> Back to EJC


Previous editions of EJC News Focus

  • November 2011
    Gordon Mills assesses the challenges we face in developing personalised medicine.
  • October 2011
    Richard Sullivan explains why the spiralling rise in healthcare costs associated with cancer is unsustainable.
  • September 2011
    Anne-Lise Borresen-Dale discusses key themes to emerge at the European Multidisciplinary Cancer Congress in Stockholm.
  • August 2011
    Jean-Charles Soria, EJC's Drug Development Editor, on the need for a new consensus on assessing toxicities.
  • July 2011
    EJC editor-in-chief Alexander Eggermont on recent advances in melanoma treatment.
  • June 2011
    Jean-Yves Blay discusses how EORTC is adapting to the new environment for research.
  • April/May 2011
    Cora Sternberg reveals exciting developments in the treatment of prostate cancer.
  • March 2011
    EJC's editor for gastrointestinal cancers, Eric van Cutsem, discusses the disappointing findings of recent trials of bevacizumab in colon cancer
  • February 2011
    Michel Coleman from the London School of Hygiene and Tropical Medicine discusses a comparison of cancer survival rates in different countries.
  • January 2011
    Jan Willem Coebergh discusses a paper relating to the NELSON lung cancer trial.

EJC News Focus – November 2011

Loading EJC News Focus video


Many studies presented at the 2011 European Multidisciplinary Cancer Congress (Stockholm, Sweden - 23-27 September, 2011) take us a step closer to the reality of personalised medicine and an individual treatment regimen for each patient. Breast cancer has been in the vanguard of progress; once considered a single disease, it is now thought to comprise 8, or even 12 subtypes, many of which are treated differently.

This stratification has been partly responsible for steadily improving outcomes, and at the opening session, Gordon Mills (MD Anderson Centre, Texas, USA) said this success demonstrates the potential of the approach. But he also said that personalised medicine is more challenging than we’re acknowledging and it could be a long time before it becomes broadly applicable.